Ascendis Pharma AS (ASND)
129.81
+7.17
(+5.85%)
USD |
NASDAQ |
Nov 22, 16:00
134.49
+4.68
(+3.61%)
After-Hours: 20:00
Ascendis Pharma Cash from Financing (Quarterly)
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 20.01M |
| December 31, 2023 | -7.422M |
| September 30, 2023 | 156.09M |
| June 30, 2023 | -2.529M |
| March 31, 2023 | -0.754M |
| December 31, 2022 | 20.09M |
| September 30, 2022 | -22.94M |
| June 30, 2022 | -25.03M |
| March 31, 2022 | 446.31M |
| December 31, 2021 | -22.87M |
| September 30, 2021 | 436.93M |
| June 30, 2021 | 1.676M |
| March 31, 2021 | 0.0241M |
| December 31, 2020 | -4.436M |
| September 30, 2020 | 684.23M |
| June 30, 2020 | 9.680M |
| March 31, 2020 | -1.233M |
| December 31, 2019 | 8.481M |
| September 30, 2019 | -3.232M |
| June 30, 2019 | 3.140M |
| March 31, 2019 | 544.19M |
| Date | Value |
|---|---|
| December 31, 2018 | 4.743M |
| September 30, 2018 | -3.853M |
| June 30, 2018 | -2.768M |
| March 31, 2018 | 241.90M |
| December 31, 2017 | 13.93M |
| September 30, 2017 | 126.61M |
| June 30, 2017 | 0.0225M |
| March 31, 2017 | 0.686M |
| December 31, 2016 | 129.29M |
| September 30, 2016 | 0.137M |
| June 30, 2016 | 0.5773M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | -0.1727M |
| September 30, 2015 | 4.177M |
| June 30, 2015 | -1.095M |
| March 31, 2015 | 114.43M |
| December 31, 2014 | 64.24M |
| September 30, 2014 | -0.5354M |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-25.03M
Minimum
Jun 2022
684.23M
Maximum
Sep 2020
94.24M
Average
0.8503M
Median
Cash from Financing (Quarterly) Benchmarks
| Novo Nordisk AS | -2.741B |
| Evaxion Biotech AS | -- |
| Akari Therapeutics PLC | -0.443M |
| Biodexa Pharmaceuticals PLC | -- |
| TC BioPharm (Holdings) PLC | 1.183M |
Cash from Financing (Quarterly) Related Metrics
| Free Cash Flow Yield | -6.21% |